Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

Dancady1 Mar. 3 at 4:40 PM

$INKT hmm most likely going under 10

0 · Reply

BenUnknown Feb. 26 at 5:19 PM

$INKT ImmunityBio’s latest earnings report highlighting their 3-year plan. Good to see iNKT cells at the tail end for sepsis

1 · Reply

Dancady1 Feb. 25 at 9:06 PM

$INKT just crashes … not funny lol

0 · Reply

Biotechguy21 Feb. 25 at 4:51 PM

$AGEN the pos games are almost over from this ceo and his team. look at $INKT and $PTIX to see what he has been upto. All three are pos companies and are almost broke. 🤡🤡🤡🤡🤡

0 · Reply

Spartrap Feb. 25 at 4:10 PM

$INKT couldn't IBRX simply fork some 2-3% shares in a 5:1 or 6:1 all shares merger? They have an absurdly high MC which makes it difficult for them to raise any decent amount and they are too low on cash for a pship, so I guess going all shares would make sense. Especially MINK-215 looks fully aligned with IBRX's goals and would be a nice addition to their pipeline. It might be a tad too early for that though.

0 · Reply

Spartrap Feb. 21 at 1:17 AM

$INKT so it sort of feels like the GC study is going to be buried, doesn't it. I like the chances in pulmonary/ards but the ETA is unclear. Also what do we think of a company that doesn't update its corporate deck for 18 months.. All in all this company looking a tad derelict and forsaken rn - needs to step up its game urgently

1 · Reply

Guptasulo Feb. 20 at 4:18 PM

$INKT Greatly to benefit INKT https://www.pharmexec.com/view/fda-removes-two-study-requirement-new-drug-approval-process-report?utm_source

0 · Reply

Dancady1 Feb. 19 at 6:33 PM

$INKT Bikini bottom ?

0 · Reply

BillionerOfKing Feb. 18 at 7:26 PM

$INKT Current Stock Price: $10.99

0 · Reply

Biotechguy21 Feb. 18 at 12:23 PM

$AGEN $INKT $PTIX what do you think when you see this pic? 😂😂😂😂

0 · Reply

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

Jan 8, 2026, 12:00 PM EST - 7 weeks ago

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Nov 20, 2025, 11:42 AM EST - 3 months ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Nov 14, 2025, 12:11 PM EST - 3 months ago

MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript

$MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025$

Nov 7, 2025, 9:00 AM EST - 4 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Sep 29, 2025, 7:30 AM EDT - 5 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 25, 2025, 7:30 AM EDT - 5 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

Sep 18, 2025, 7:30 AM EDT - 5 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Aug 14, 2025, 4:15 PM EDT - 7 months ago

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 7 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 15, 2025, 8:21 AM EDT - 8 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 11, 2025, 12:33 PM EDT - 8 months ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jun 10, 2025, 1:33 PM EDT - 9 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 9 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 1:21 PM EDT - 10 months ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 10 months ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Mar 18, 2025, 11:28 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 1 year ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 1 year ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Nov 14, 2024, 10:47 AM EST - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 2:51 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 1 year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 2 years ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 8, 2024, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 2:20 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 2 years ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Nov 9, 2023, 7:00 AM EST - 2 years ago

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 3, 2023, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Oct 30, 2023, 8:00 AM EDT - 2 years ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Dancady1 Mar. 3 at 4:40 PM

$INKT hmm most likely going under 10

0 · Reply

BenUnknown Feb. 26 at 5:19 PM

$INKT ImmunityBio’s latest earnings report highlighting their 3-year plan. Good to see iNKT cells at the tail end for sepsis

1 · Reply

Dancady1 Feb. 25 at 9:06 PM

$INKT just crashes … not funny lol

0 · Reply

Biotechguy21 Feb. 25 at 4:51 PM

$AGEN the pos games are almost over from this ceo and his team. look at $INKT and $PTIX to see what he has been upto. All three are pos companies and are almost broke. 🤡🤡🤡🤡🤡

0 · Reply

Spartrap Feb. 25 at 4:10 PM

0 · Reply

Spartrap Feb. 21 at 1:17 AM

1 · Reply

Guptasulo Feb. 20 at 4:18 PM

$INKT Greatly to benefit INKT https://www.pharmexec.com/view/fda-removes-two-study-requirement-new-drug-approval-process-report?utm_source

0 · Reply

Dancady1 Feb. 19 at 6:33 PM

$INKT Bikini bottom ?

0 · Reply

BillionerOfKing Feb. 18 at 7:26 PM

$INKT Current Stock Price: $10.99

0 · Reply

Biotechguy21 Feb. 18 at 12:23 PM

$AGEN $INKT $PTIX what do you think when you see this pic? 😂😂😂😂

0 · Reply

Tredin3 Feb. 17 at 3:05 AM

$INKT 👀

1 · Reply

swstutz Feb. 17 at 1:26 AM

$AGEN lots of talk about $INKT and $IBRX . Any thoughts around IBRX buying INKT and Garo bringing Jen back into Agenus and using the funds to extend the runway?

3 · Reply

mikesterz7 Feb. 17 at 12:36 AM

$INKT PT $35

0 · Reply

pat_soons_shlong Feb. 17 at 12:28 AM

$INKT does someone have a 2026 MiNK catalyst dates estimate on hand? Mostly info about where they are at within their phases of approval for their therapy’s? I’ve been in IBRX for 2 years now and have been learning a little bit about MiNK over the past few months. I would greatly appreciate it!

0 · Reply

BenUnknown Feb. 16 at 11:48 PM

$INKT For those on this board exclusively. Patrick Soon-Shiong (founder of ImmunityBio) put on the first US-Saudi biotech alliance. Now Saudi is hosting the second Saudi-US conference this week in Saudi. There is clearly some connection here and I’m quite excited. Been buying MiNK slowly for a little while now. Could see some really good unexpected news this week for MiNK!

0 · Reply

BenUnknown Feb. 16 at 11:43 PM

$IBRX $INKT Wouldn’t be surprised if Patrick brings MiNK into the convo again. They attended the first US-Saudi biotech environment. Their iNKT cells would be a huge help to our NK therapy and would play excellently with ANKTIVA. I wouldn’t even be surprised if the good doctor buys them out as a subsidiary of ImmunityBio. Anywho, just a dot I think I’ve connected… Super excited for tomorrow!!!

1 · Reply

InfernoDrake Feb. 16 at 11:20 PM

$QNTM $APPS $CPIX $INKT 0{}

0 · Reply

Biotechguy21 Feb. 16 at 8:48 PM

$AGEN this pos loves to flush money down the drain 24/7. Study up on these other two pos companies $PTIX $INKT and tell me what you notice 👀🤡😂💩💰

0 · Reply

2_logs_higher Feb. 8 at 2:48 AM

$AGEN & $INKT

3 · Reply

2_logs_higher Feb. 5 at 4:24 PM

$AGEN & $INKT $PTIX Articles like this make one wonder how much G pissed off the FDA and how long they will hold a grudge. Maybe the FDA should just say, once G departs, we will approve. Nothing soon for PTIX as a result of this article. https://www.statnews.com/2026/02/04/psilocybin-depression-psychedelic-drug-fast-track-blocked/

1 · Reply

Spartrap Feb. 4 at 4:15 PM

$INKT no market reaction but I like the findings. It bodes well for efficacy in ARDS. IPF is a tough nut to crack as are all fibrotic diseases but the prospect is interesting

1 · Reply

cotsl Feb. 4 at 12:57 PM

$INKT Great 9:30pm press release on new data presentation regarding iNKT; low float; on 07/11/2025 surged 730% on an iNKT publication.

1 · Reply

Market Cap	51.17M
Revenue (ttm)	0.00
Net Income (ttm)	-9.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	6,800
Avg Vol	10,426
Day's Range	N/A - N/A
Shares Out	4.69M
Stochastic %K	4%
Beta	0.35
Analysts	Strong Sell
Price Target	$39.00